The U.S. Food and Drug Administration said on November 30 the regulatory agency was evaluating the effectiveness of authorized Covid-19 vaccines against the Omicron coronavirus variant and expects to have more information in the next few weeks.
If you are not happy with the results below please do another search
50 search results for:
One day after Bay Area-based Olema Pharmaceuticals announced that falsified information regarding its Phase I/II breast cancer data was circulating across the Internet, the company released topline data for OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN).
The Centers for Disease Control and Prevention (CDC) shifted its recommendation on adults getting a booster Covid-19 vaccine to now include everyone ages 18 years and older as the threat of the new Omicron variant looms.
Merck & Co. Inc.’s experimental Covid-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on NOvember 30.
GSK hired one of the scientists behind Pfizer’s mRNA COVID-19 shot, Phil Dormitzer, as the company’s global head of R&D for vaccines and he will join the British drugmaker from Dec. 3.
The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.
The U.S. Centers for Disease Control and Prevention said on November 29 everyone aged 18 years and older should get a booster shot, as the CDC looks to tackle a new and highly infectious strain of the coronavirus that is quickly spreading across the globe.
Reinfections with the virus that causes COVID-19 are rarely severe, new findings suggest. Additionally, researchers say in COVID-19 survivors struggling with lingering shortness of breath for which doctors do not have an explanation, cardiac stress testing may help identify the cause of the problem.
BioNTech, Moderna and Johnson & Johnson are working on vaccines that specifically target Omicron in case their existing shots are not effective against the new coronavirus variant, the companies said on November 29.
The New York Times profiled the success story of a type 1 diabetes patient who was dosed with Vertex Pharmaceuticals’ experimental fully differentiated pancreatic islet cell replacement therapy, and after an infusion of VX-880, he began to produce his own insulin.